|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Deciphera Pharmaceuticals, Inc. (DCPH) |
|
|
$25.59 0.00 (0.00%) as of 4:30 Mon 6/10
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
60,930,000 |
Market
Cap: |
1.56(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$10.11 - $25.59 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Deciphera Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing medicines to improve the lives of people with cancer. QINLOCK, Co.'s switch-control kinase inhibitor, was developed using Co.'s proprietary drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor. In addition, Co. has identified and developed various product candidates from its platform into clinical studies, including vimseltinib and DCC-3116. Co. is studying vimseltinib in a Phase 3 study in patients with tenosynovial giant cell tumor. DCC-3116 is designed to inhibit autophagy, a key tumor survival mechanism in cancer cells.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
1,687,666 |
Total Buy Value |
$0 |
$0 |
$0 |
$30,291,232 |
Total People Bought |
0 |
0 |
0 |
3 |
Total Buy Transactions |
0 |
0 |
0 |
3 |
Total Shares Sold |
0 |
18,277 |
107,720 |
171,737 |
Total Sell Value |
$0 |
$276,125 |
$1,495,560 |
$2,560,942 |
Total People Sold |
0 |
4 |
5 |
6 |
Total Sell Transactions |
0 |
8 |
20 |
38 |
End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Sherman Matthew L |
EVP & Chief Medical Officer |
|
2021-02-16 |
4 |
S |
$48.87 |
$6,451 |
D/D |
(132) |
37,286 |
|
20% |
|
Flynn Daniel Lee |
Chief Scientific Officer |
|
2021-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
11,100 |
17,632 |
|
- |
|
Flynn Daniel Lee |
Chief Scientific Officer |
|
2021-02-16 |
4 |
S |
$48.87 |
$24,826 |
D/D |
(508) |
6,532 |
|
20% |
|
Kelly Thomas Patrick |
Chief Financial Officer |
|
2021-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
11,100 |
17,616 |
|
- |
|
Kelly Thomas Patrick |
Chief Financial Officer |
|
2021-02-16 |
4 |
S |
$48.87 |
$25,608 |
D/D |
(524) |
6,516 |
|
20% |
|
Taylor Michael Douglas |
Director |
|
2021-02-01 |
4 |
AS |
$44.34 |
$361,872 |
D/D |
(8,000) |
0 |
|
-23% |
|
Taylor Michael Douglas |
Director |
|
2021-02-01 |
4 |
OE |
$1.89 |
$15,120 |
D/D |
8,000 |
8,000 |
|
- |
|
Hoerter Steven L. |
President and CEO |
|
2021-01-21 |
4 |
OE |
$25.40 |
$27,381 |
D/D |
1,078 |
43,845 |
|
- |
|
Bristol James Arthur |
Director |
|
2021-01-15 |
4 |
AS |
$50.21 |
$352,039 |
D/D |
(7,000) |
0 |
|
-32% |
|
Bristol James Arthur |
Director |
|
2021-01-15 |
4 |
OE |
$3.95 |
$27,650 |
D/D |
7,000 |
7,000 |
|
- |
|
Taylor Michael Douglas |
Director |
|
2021-01-04 |
4 |
AS |
$55.80 |
$1,072,497 |
D/D |
(19,000) |
0 |
|
-42% |
|
Taylor Michael Douglas |
Director |
|
2021-01-04 |
4 |
OE |
$1.89 |
$35,910 |
D/D |
19,000 |
19,000 |
|
- |
|
Sherman Matthew L |
EVP & Chief Medical Officer |
|
2020-12-09 |
4 |
OE |
$34.43 |
$7,127 |
D/D |
207 |
37,418 |
|
- |
|
Taylor Michael Douglas |
Director |
|
2020-12-01 |
4 |
AS |
$60.23 |
$1,157,142 |
D/D |
(19,000) |
0 |
|
-28% |
|
Taylor Michael Douglas |
Director |
|
2020-12-01 |
4 |
OE |
$1.89 |
$35,910 |
D/D |
19,000 |
19,000 |
|
- |
|
Sherman Matthew L |
EVP & Chief Medical Officer |
|
2020-11-16 |
4 |
OE |
$34.43 |
$92,858 |
D/D |
2,697 |
37,211 |
|
- |
|
Taylor Michael Douglas |
Director |
|
2020-11-04 |
4 |
AS |
$64.67 |
$971,987 |
D/D |
(15,000) |
0 |
|
-32% |
|
Taylor Michael Douglas |
Director |
|
2020-11-04 |
4 |
OE |
$1.89 |
$28,350 |
D/D |
15,000 |
15,000 |
|
- |
|
Taylor Michael Douglas |
Director |
|
2020-11-02 |
4 |
AS |
$57.03 |
$1,343,926 |
D/D |
(23,315) |
0 |
|
-26% |
|
Taylor Michael Douglas |
Director |
|
2020-11-02 |
4 |
OE |
$1.89 |
$44,065 |
D/D |
23,315 |
23,315 |
|
- |
|
Bristol James Arthur |
Director |
|
2020-10-09 |
4 |
AS |
$53.35 |
$1,261,069 |
D/D |
(23,541) |
0 |
|
-22% |
|
Bristol James Arthur |
Director |
|
2020-10-09 |
4 |
OE |
$1.89 |
$44,492 |
D/D |
23,541 |
23,541 |
|
- |
|
Sherman Matthew L |
EVP & Chief Medical Officer |
|
2020-10-02 |
4 |
D |
$51.15 |
$134,618 |
D/D |
(2,632) |
34,128 |
|
- |
|
Taylor Michael Douglas |
Director |
|
2020-10-01 |
4 |
AS |
$51.52 |
$6,450,484 |
D/D |
(125,000) |
0 |
|
-5% |
|
Taylor Michael Douglas |
Director |
|
2020-10-01 |
4 |
OE |
$1.89 |
$236,250 |
D/D |
125,000 |
125,000 |
|
- |
|
290 Records found
|
|
Page 5 of 12 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|